Bempegaldesleukin
- Generic Name
- Bempegaldesleukin
- Drug Type
- Biotech
- CAS Number
- 1939126-74-5
- Unique Ingredient Identifier
- BNO1JG5MZC
- Background
Bempegaldesleukin is under investigation in clinical trial NCT03729245 (A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)).
BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)
- Conditions
- Metastatic Head and Neck CancerRecurrent Head and Neck Cancer
- Interventions
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 1
- Registration Number
- NCT04969861
- Locations
- 🇦🇹
Universitätsklinikum Salzburg, Landeskrankenhaus,, Salzburg, Salzburg Bundesland, Austria
🇬🇷Attikon University General Hospital, Athens, Attiki, Greece
🇺🇸Nebraska Methodist Hospital, Omaha, Nebraska, United States
Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2021-06-23
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 5
- Registration Number
- NCT04936841
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19
- Conditions
- Covid-19Coronavirus Disease 2019
- Interventions
- First Posted Date
- 2020-11-27
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT04646044
- Locations
- 🇺🇸
SMS Clinical Research, LLC, Mesquite, Texas, United States
🇺🇸Clinical Site Partners - Winter Park - HyperCore -PPDS, Winter Park, Florida, United States
🇺🇸A G A Clinical Trials - HyperCore - PPDS, Hialeah, Florida, United States
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
- Conditions
- Squamous Cell Carcinoma of the Head and Neck (SCCHN)Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Interventions
- First Posted Date
- 2019-08-09
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3
- Registration Number
- NCT04052204
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇧🇪GZA Ziekenhuizen campus Sint-Augustinus, Wilrijk, Antwerpen, Belgium
A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)
- First Posted Date
- 2018-12-11
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Calithera Biosciences, Inc
- Registration Number
- NCT03772288
- Locations
- 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇨🇦Alberta Health Services, Calgary, Alberta, Canada
🇨🇦Jewish General Hospital, Montreal, Quebec, Canada
A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 783
- Registration Number
- NCT03635983
- Locations
- 🇺🇸
Local Institution - 0187, Tucson, Arizona, United States
🇺🇸Local Institution - 0001, Houston, Texas, United States
🇺🇸Local Institution - 0064, Fairfax, Virginia, United States
A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer
- Conditions
- Locally Advanced or Metastatic Solid Tumours
- Interventions
- Biological: VB10.NEO
- First Posted Date
- 2018-06-07
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Nykode Therapeutics ASA
- Target Recruit Count
- 41
- Registration Number
- NCT03548467
- Locations
- 🇩🇪
University Hospital Heidelberg, NCT, Im Neuenheimer Feld 460, Heidelberg, Germany
🇩🇪Universitätsmedizin Mannheim, Mannheim, Germany
🇩🇪Krankenhaus Nordwest gGmbH, Frankfurt, Germany
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
- Conditions
- Merkel Cell CarcinomaTriple Negative Breast CancerHead and Neck Squamous Cell CarcinomaColorectal CancerMelanomaSarcomaRenal Cell Carcinoma
- Interventions
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 64
- Registration Number
- NCT03435640
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸HonorHealth, Scottsdale, Arizona, United States
A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma
- First Posted Date
- 2017-09-13
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 88
- Registration Number
- NCT03282344
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center (only recruiting to the Vascular/Angiosarcoma cohort), New York, New York, United States
🇺🇸MD Anderson Cancer Center (only recruiting to the Vascular/Angiosarcoma cohort), Houston, Texas, United States
Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2017-05-03
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 162
- Registration Number
- NCT03138889
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇩🇪Lungenklinik Hemer, Hemer, Germany
🇺🇸Highlands Oncology Group, PA - North Hills, Fayetteville, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.